Suciraslimab (SM03) is an anti-human CD22 monoclonal antibody. Suciraslimab inhibits NLRP3 and ASC signaling. Suciraslimab suppresses cytokine (IL-1beta, IL-12, IL-23) secretion and alpha4 integrin expression. Suciraslimab improves working memory and neuroinflammation[1]. Suciraslimab isotype control product: Human IgG1 kappa, Isotype Control (HY-P99001).